<DOC>
	<DOCNO>NCT00078325</DOCNO>
	<brief_summary>The primary objective study determine whether treatment Armodafinil ( CEP-10953 ) effective placebo treatment patient excessive sleepiness associate obstructive sleep apnea/hypopnea syndrome ( OSAHS ) measure mean sleep latency Maintenance Wakefulness Test ( MWT ) ( 30-minute version ) ( average 4 naps 0900 , 1100 , 1300 , 1500 ) Clinical Global Impression Change ( CGI-C ) rating ( related general condition ) week 12 , last post-baseline visit .</brief_summary>
	<brief_title>Armodafinil ( CEP-10953 ) Treatment Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome ( OSAHS )</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Disorders Excessive Somnolence</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>Patients include study follow criterion meet : 1 . Written inform consent obtain . 2 . The patient outpatient , man woman ethnic origin , 18 65 year age ( inclusive ) . 3 . The patient complaint excessive sleepiness despite nCPAP therapy effective regular user nCPAP therapy . 4 . The patient current diagnosis OSAHS accord International Classification Sleep Disorders ( ICSD ) criterion . 5 . The patient meet follow nCPAP therapy requirement : Adequate education intervention effort encourage nCPAP therapy use must document . A patient 's nCPAP therapy regimen must stable least 4 week . nCPAP therapy show effective , effectiveness define apneahypopnea index ( AHI ) 10 less nocturnal PSG , , opinion investigator , nCPAP effective therapy . Following demonstration effectiveness , evidence regular nCPAP usage must show 2week evaluation period ( ie , nCPAP usage least 4 hours/night least 70 % night ) . 6 . The patient good health determine medical psychiatric history , physical examination , ECG , serum chemistry hematology . 7 . Women must surgically sterile , 2 year postmenopausal , , childbearing potential , use medically accept method birth control ( ie , barrier method spermicide , steroidal contraceptive [ oral , implanted , DepoProvera contraceptives must use conjunction barrier method ] , intrauterine device [ IUD ] ) agree continue use method duration study . 8 . The patient Clinical Global Impression Severity Illness ( CGIS ) rating 4 . 9 . The patient ESS score 10 . 10 . The patient medical psychiatric disorder could account excessive sleepiness . 11 . The patient able complete self rating scale computerbased test . 12 . The patient willing able comply study restriction attend regularly schedule clinic visit specify protocol . Patients exclude participate study 1 follow criterion meet : 1. clinically significant , uncontrolled medical psychiatric condition ( treat untreated ) 2. probable diagnosis current sleep disorder OSAHS 3. consumes caffeine include coffee , tea and/or caffeine contain beverage food average 600 mg caffeine per day 4. use prescription drug disallow protocol clinically significant use thecounter ( OTC ) drug within 7 day second screening visit 5. history alcohol , narcotic , drug abuse define Diagnostic Statistical Manual Mental Disorders American Psychiatric Association , 4th Edition ( DSM IV ) 6. positive urine drug screen ( UDS ) 7. clinically significant deviation normal physical examination 8. pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) 9. used investigational drug within 1 month initial screen visit 10. disorder may interfere drug absorption , distribution , metabolism , excretion ( include gastrointestinal surgery ) 11. know clinically significant drug sensitivity stimulant modafinil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Excessive Sleepiness</keyword>
	<keyword>Obstructive Sleep Apnea</keyword>
	<keyword>Obstructive Sleep Hypopnea</keyword>
	<keyword>nCPAP</keyword>
	<keyword>Cephalon</keyword>
	<keyword>Cephalon , Inc</keyword>
	<keyword>NUVIGIL</keyword>
</DOC>